News | August 26, 2021
Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra
Domestic business was up 41.9% YoY and 27.7% QoQ
Domestic business was up 41.9% YoY and 27.7% QoQ
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
This achievement validates global demand and catapults Wanbury into high-growth acceleration
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
A PhD in Pharmaceutical Sciences, Dr Singh has led global regulatory audits, product validations, and quality systems spanning therapeutic formulations, dietary supplements, and functional foods
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Subscribe To Our Newsletter & Stay Updated
